Cognitive Enhancement

On August 5, 2026, the FDA approved Orzeyful, a new drug for narcolepsy, a condition that affects roughly 120,000 Americans. It works by improving wakefulness, attention and motivation — the same things any employer, student or soldier would happily pay to have more of. That's the real story here, not a narcolepsy drug, but the first real test of how far the line between treating an illness and enhancing a healthy brain can bend. Nobody is claiming Orzeyful will end up in a healthy person's medicine cabinet, but drugs built for one purpose have a track record of finding a second, far more lucrative one, and once a pill can sharpen focus in the sick, keeping it away from the well gets harder by the year. That is the shift worth watching: what it would mean for who can afford access, for turning ordinary tiredness into a diagnosis, for misuse, and for a definition of “normal” human performance that keeps sliding the moment “enhanced” goes on sale.